1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

"Faulty" economic analysis results in preliminary NICE no for Novartis' DMO

 
• By Francesca Bruce

NICE, the health technology appraisal institute for England and Wales, has said a preliminary no to Novartis' Lucentis (ranibizumab) for patients with visual impairment due to diabetic macular oedema (DMO) for use on the National Health Service. The firm had presented a "faulty" economic analysis that failed to reflect UK clinical practice, said NICE.

NICE, the health technology appraisal institute for England and Wales, has said a preliminary no to Novartis' Lucentis (ranibizumab) for patients with visual impairment due to diabetic macular oedema (DMO) for use on the National Health Service. The firm had presented a "faulty" economic analysis that failed to reflect UK clinical practice, said NICE.

Today's appraisal consultation document (ACD) comes just two months after Novartis secured EU approval for the VEGF receptor antagonist for vision loss caused by DMO (scripintelligence

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.

More from Therapeutic Category

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.